Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Other Accumulated Expenses: 2022-2023

  • Dianthus Therapeutics' Other Accumulated Expenses was N/A to $279,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $279,000, marking a year-over-year change of. This contributed to the annual value of $364,000 for FY2022, which is N/A change from last year.
  • As of Q2 2023, Dianthus Therapeutics' Other Accumulated Expenses stood at $279,000, which was up 24.55% from $224,000 recorded in Q1 2023.
  • Over the past 5 years, Dianthus Therapeutics' Other Accumulated Expenses peaked at $364,000 during Q4 2022, and registered a low of $224,000 during Q1 2023.
  • Its 2-year average for Other Accumulated Expenses is $289,000, with a median of $279,000 in 2023.